Disease-modifying drugs for multiple sclerosis must be globally available according to therapeutic guidelines suitable to different regions of the world
Saved in:
| Main Author: | Maria José Sá |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Thieme Revinter Publicações
2012-10-01
|
| Series: | Arquivos de Neuro-Psiquiatria |
| Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2012001000001&lng=en&tlng=en |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Multiple Sclerosis Disease-Modifying Treatment Algorithms: 2025 Positioning of the Portuguese Multiple Sclerosis Study Group
by: Carlos Capela, et al.
Published: (2025-05-01) -
Patients’ satisfaction with and views about treatment with disease-modifying drugs in multiple sclerosis
by: Caroline Vieira Spessotto, et al.
Published: (2016-08-01) -
The world must prepare now for the next pandemic
by: Marine Buissonnière, et al.
Published: (2021-03-01) -
EVALUATION OF IMMUNOTOXICITY OF THE THERAPEUTIC DRUG PROLONGED ACTION FOR MULTIPLE SCLEROSIS ON RHESUS MONKEYS
by: A. B. Dzheliya, et al.
Published: (2015-10-01) -
Multiple sclerosis and pregnancy. Impact of multiple sclerosis disease-modifying therapy on the health of newborns
by: T. I. Yakushina
Published: (2021-02-01)